Q32 BIO INC.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
- Conditions
- Lupus Nephritis (LN)C3 (Complement Component 3) GlomerulopathyIgA Nephropathy
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06419205
- Locations
- 🇺🇸
Denver, Denver, Colorado, United States
🇺🇸Minneapolis, Minneapolis, Minnesota, United States
🇺🇸Las Vegas, Las Vegas, Nevada, United States
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
- Conditions
- Alopecia Areata
- Interventions
- Drug: bempikibart (ADX-914)
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06018428
- Locations
- 🇺🇸
Scottsdale, Arizona, Scottsdale, Arizona, United States
🇺🇸Fayetteville, Arkansas, Fayetteville, Arkansas, United States
🇺🇸Hot Springs, Arkansas, Hot Springs, Arkansas, United States
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05509023
- Locations
- 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States
🇺🇸Dermatology of Seattle & Bellevue, Seattle, Washington, United States
🇺🇸Dermatology Specialists of Spokane, Spokane, Washington, United States
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II
- Conditions
- Mucopolysaccharidosis II
- Interventions
- Biological: Genetic HMI-203
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Homology Medicines, Inc
- Registration Number
- NCT05238324
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax, Virginia, United States
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Homology Medicines, Inc
- Target Recruit Count
- 3
- Registration Number
- NCT05222178
- Locations
- 🇺🇸
The Community Health Clinic, Topeka, Indiana, United States
🇺🇸Clinic for Special Children, Lancaster, Pennsylvania, United States
Natural History Clinical Study in Adult PKU
- Conditions
- PhenylketonuriasPKU
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Homology Medicines, Inc
- Target Recruit Count
- 7
- Registration Number
- NCT04768348
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04485481
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Long-Term Follow Up Study of Subjects Previously Administered HMI 102
- Conditions
- PhenylketonuriaPAH Deficiency
- Interventions
- Genetic: HMI-102
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Homology Medicines, Inc
- Target Recruit Count
- 21
- Registration Number
- NCT04348708
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Gene Therapy Clinical Study in Adult PKU
- Conditions
- PhenylketonuriasPAH Deficiency
- Interventions
- Genetic: HMI-102
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Homology Medicines, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT03952156
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸The University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States